Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
pharmafile | April 20, 2016 | News story | Research and Development, Sales and Marketing | Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple sclerosis (RRMS).
The ongoing Phase II CAMMS223 study showed that, over 10 years of follow-up, 76% of patients were shown to be free from 6-month confirmed disability worsening. Furthermore, a low annualised relapse rate (ARR) was maintained (0.08) over the period, while long term safety was observed in the trial patients that were consistent with other trials for Lemtrada.
Professor Alasdair Coles, lead investigator of the study from the University of Cambridge school of clinical medicine, says: “These data provide further evidence of the long term response with Lemtrada in treatment-naïve patients with relapsing-remitting MS. It is remarkable that such infrequent dosing with Lemtrada offers stability or improvement of disability over ten years. These findings confirm that Lemtrada is a valid treatment approach for people with multiple sclerosis, without the need for continuous treatment.”
More than 100,000 people in the UK have MS, with around 85% of those diagnosed with relapsing remitting multiple sclerosis. Lemtrada is the second of Sanofi Genzyme’s treatments for MS to have received approval from NICE for use in the NHS in England and Wales.
Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme, comments: “We are very pleased with these new data, which are part of our extensive clinical development programme and our commitment to the field of MS. Being able to offer this treatment option, which was discovered and developed in the UK to clinicians and their patients, is of incredible importance to us.”
The data was presented at the American Academy of Neurology 2016 Annual Meeting in Vancouver.
Sean Murray
Related Content
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
Sanofi to acquire Inhibrx for approximately $1.7bn
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …
AstraZeneca and Sanofi’s Beyfortus approved in China
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the …
